BASi has announced the awarding of the new European patent for their Culex Automated In Vivo Sampling System.
BASi Recieves a European Patent for Culex
(January 6, 2008; WARWICKSHIRE, UK)-BASi is proud to announce the awarding of the new European patent for their Culex® Automated In Vivo Sampling System. The patent is valid until 2019 and is effective in Germany, Denmark, France, UK and Sweden.
The Culex Automated In Vivo Sampling System is designed to collect pharmacokinetic and pharmacodynamic (PK/PD) data during the course of drug metabolism experiments. The Culex systems can collect blood, bile, urine, feces, dialysates and more – with greatly reduced trauma and stress from awake, freely moving animals. In addition, an electronic report on both the dosing and the blood sampling experiments is generated automatically.
Culex’s versatility makes possible a wide variety of PK/PD studies in small rodents, greatly reducing the number of animals used whilst increasing the number of samples per animal, and allowing dosing and sampling of animals, day or night.
With Culex, researchers gain the unique opportunity to undertake full PK/PD studies in the same animal. In addition, researchers can monitor a wide range of physiological parameters such as blood pressure, body temperature, respiratory rates, ECG, urinary frequency and animal movement alongside more traditional pharmacokinetic parameters.
BASi has recently introduced the Culex®-L, Automated Large Animal In Vivo Sampling System. This instrument utilizes the same concept as the popular rodent-orientated Culex system but for pigs and other larger mammals.
About BASi
BASi provides contract research services and specialized instrumentation and accessories for electrochemistry and in vivo sampling products to the world’s leading drug development companies. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new drugs to market. Visit www.BASInc.com for more information about BASi.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.